Endothelial dysfunction and interaction between inflammation and coagulation in sepsis and systemic inflammatory response syndrome (SIRS)

HealthMED

Volumn 6, Issue 4, 2012, Pages 1309-1314

  Mihajlovic, Dunja ^a   Draskovic, Biljana ^b   Brkic, Snezana ^c   Mitic, Gorana ^d   Lendak, Dajana ^c  

^a Clinical Centre of Vojvodina   (Serbia)

^b Institute of Child and Adolescent Health Care of Vojvodina   (Serbia)

^c Clinic for infectious diseases   (Serbia)

^d Laboratory medicine centre   (Serbia)

Author keywords

Coagulation; Endothelium; Sepsis; Systemic inflammatory response syndrome

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; ANTITHROMBIN III; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 7A; CELL ADHESION MOLECULE; CYTOKINE; DROTRECOGIN; IMMUNOGLOBULIN; INACTIVATED BLOOD CLOTTING FACTOR 7A; INTEGRIN; PROTEIN C; SELECTIN; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

BLEEDING; BLOOD CLOTTING; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG TREATMENT FAILURE; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84861359887     PISSN: 18402291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Helmut GA. Endothelial Cell Input. In: Aird WC, edithor. Endothelial Biomedicine. New York: Cambridge University Press; 2007.p. 227-9.
2. Adams JA. Targeting the endothelium. Signa vitae, 2010; 5 (Suppl 1): 17-23.
3. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood, 1998; 91: 3527-61.
4. Nyström PO. The systemic inflammatory response syndrome: definition and aetiology. J Antimicrob Chemother. 1998; 41(Suppl. A):1-7.
5. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Crit Care Med, 2003; 31: 1250-6.
6. Castellheim A, Brekke OL, Espeviks M. Innate immune responses to danger signals in systemic infl{ligature}ammatory response syndrome and sepsis. Scandinavian Journal of Immunology, 2009;69:479-91.
7. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003; 101: 3765-77.
8. Hoesel LM, Ward PA. The Role of the Endothelium in Systemic Infl{ligature}ammatory Response Syndrome and Sepsis. In: Aird WC, edithor. Endothelial Biomedicine. New York: Cambridge University Press; 2007. p 1294-302.
9. Levi M, Schultz M. Coagulopathy and platelet disorders in critically ill patients. Minerva Anestesiol. 2010;76(10):851-9.
10. Dhainaut JF, Shorr AF. Macias WL. Dynamic evolution of coagulopathy in the first day of severe sepsis: Relationship with mortality and organ failure. Crit Care Med. 2005; 33(2): 341-8.
11. Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006; 10: 222.
12. Levi M. Coagulation in: Cavaillon JM, Adire C. Sepsis and non-infectious systemic infl{ligature}ammation from biology to critical care. Weinheim: WILEY-VCH Verlag GmbH & Co. KgaA; 2009. p 251-78.
13. Levi M, de Jonge E, van Der Poll T. Sepsis and disseminated intravascular coagulation. J. Thromb. Thrombolysis. 2003; 16 (1-2): 43-7.
14. Harrison DG, Widder J, Grumbach I, Chen W, Weber M, Searles C. Endothelial mechanotransduction, nitric oxide and vascular infl{ligature}ammation. Journal of Internal Medicine. 2006; 259: 351-63.
15. Levi M, ten Hate C, van der Poll T. Endothelium: Interface between coagulation and infl{ligature}ammation. Crit Care Med. 2002; 30 (5 Suppl): S220-4.
16. Lau SY, Ichinos F. The role of endothelium in: Cavaillon JM, Adire C. Sepsis and non-infectious systemic infl{ligature}ammation from biology to critical care. Weinheim: WILEY-VCH Verlag GmbH & Co. KgaA; 2009. p 231-50.
17. Levi M. The coagulant response in sepsis and inflammation. Hämostaseologie 2011;30:10-6.
18. Levi M, van der Poll T. Infl{ligature}ammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26-34.
19. Myers DD, Hawley AE, Farris DM. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. Journal of vascular surgery. 2003; 38 (5):1075-89.
20. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med. 2004;10:171-8.
21. Babic N, Huskic J, Nakas-Icindic E, Tihic-Kapidzic S, Music M. New information about Von Willebrand's factor. HealthMED. 2010; 4 (1): 187-194.
22. Schouten M, Wiersinga WJ, Levi M. Infl{ligature}ammation, endothelium, and coagulation in sepsis. Journal of Leukocyte Biology. 2008; 83: 536-45.
23. Lindner H, Holler E, Ertl B, Multhoff G, Schreglmann M, Klauke I, et al. Peripheral blood mononuclear cells induce programmed cell death in human endothelial cells and may prevent repair: role of cytokines. Blood. 1997; 89: 1931-8.
24. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood.1997; 89: 2429-42.
25. Esmon CT. The interactions between infl{ligature}ammation and coagulation. Br. J. Haematol. 2005; 131: 417-43.
26. Levi M., Van der Poll T. Two-way interactions between infl{ligature}ammation and coagulation. Trends Cardiovasc. Med. 2005; 15: 254-9.
27. Esmon CT. Coagulation and inflammation. Journal of Endotoxin Research. 2003; 9(3): 192-8.
28. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. Circulation. 2004; 109:2698-704.
29. Heyderman RS, Klein NJ, Shennan GI, Levin M. Reduction of the anticoagulant activity of glycosaminoglycans on the surface of the vascular endothelium by endotoxin and neutrophils: Evaluation by an amidolytic assay. Thromb Res 1992; 67:677-85.
30. Klein NJ, Shennan GI, Heyderman RS, Levin M. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci. 1992; 102: 821-32.
31. Navarro S, Bonet E, Estelles A, Montes R, Hermida J, Martos L, et al. The endothelial cell protein C receptor: Its role in thrombosis. Thromb Res. 2011, doi:10.1016/j.thromres.2011.08.001
32. de Jonge E, Dekkers PEP, Creasey AA, Hack CE, Paulson SK, Karim A, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without infl{ligature}uencing the fibrinolytic and cytokineresponse during human endotoxemia. Blood. 2000; 95:1124-29.
33. Welty-Wolf KE, Carraway MS, Miller DL, Ortel TL, Ezban M, Ghio AJ, et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am. J. Respir. Crit. Care Med. 2001; 164: 1988-96.
34. Levi M, van der Poll T. The central role of the endothelium in the crosstalk between coagulation and inflammation in sepsis. Advances in sepsis. 2004; 3(3): 91-7.
35. Madoiwa S, Nunomiya S, Ono T, Shintani Y, Ohmori T, Mimuro J, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol. 2006; 84: 398-405.
36. Coughlin SR: Thrombin signalling and protease-activated receptors. Nature.2000; 407:258-64.
37. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med. 2002; 196: 561-4.
38. Esmon CT. Infl{ligature}ammation and thrombosis. J Thromb Haemost. 2003; 1: 1343-8.
39. Opal SM. Interactions between coagulation and infl{ligature}ammation. Scand J Infect Dis.2003; 35: 545-54.
40. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock. Intensive Care Med. 2008; 34: 17-60.
41. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Recombinant human protein C Worldwide evaluation in severe sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein c for severe sepsis. N Engl J Med. 2001; 344: 699-709.
42. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, et al. Administration of Drotrecogin Alfa(Activated) in early stage severe sepsis (ADDRESS) study group: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005; 353: 1332-41.
43. Finfer S, Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, et al. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008, 34:1935-47.
44. University of Versailles. Activated protein C and corticosteroids for human septic shock (APROCCHS). [Online] 2011. [cited 2011 October 19]; Available from http://clinicaltrials.gov/ct2/show/NCT00625209
45. Creasey AA, Chang AC, Feigen L, Wün TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993; 91(6): 2850-60.
46. Levi M., ten Cate H, Bauer KA, van der Poll T, Edgington TS, Büller HR, et al. (1994) Inhibition of endotoxin-induced activation ofcoagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J. Clin. Invest.1994; 93: 114-20.
47. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, et al. Antithrombin III in patients with severe sepsis, A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, doubleblind trials with antithrombin III in severe sepsis. Intensive Care Medicine. 1998; 24(7): 663-72.
48. Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Intensive Care Med.2004; 30:1032-40.
49. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, et al. High-dose antithrombin III in severe sepsis A randomized controlled trial. JAMA. 2001; 286 (15): 1869-78.
50. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of Tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA. 2003;290(2):238-47.
51. Munford RS, Sufredini AF. Sepsis, severe sepsis, and septic shock. In: Mandell, Bennett, Dolin. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone; 2010. p 987-1010.